UTR Therapeutics Inc. Announces U.S. FDA Orphan Drug Designation and Rare Pediatric Disease Designation for UTRxMYCN M1-14

U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) underscore UTRxMYCN M1-14's therapeutic targeting of the "undruggable" MYCN (N-MYC) in rare, aggressive soft tissue sarcomas, addressing a significant unmet clinical need in pediatric and adult sarcomas....

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.